ClinicalTrials.gg
RecruitingNCT06220006PULSED-ICE-CMRUpdated Apr 7, 2026

Lesion Formation With Pulsed Field Versus Cryobaloon Ablation as Assessed by Cardiac Magnetic Resoncance

An interventional study of Pulmonary vein isolation in Atrial Fibrillation, sponsored by Hospital Clinic of Barcelona. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-07.

Sponsored by Hospital Clinic of Barcelona · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Atrial Fibrillation by Hospital Clinic of Barcelona — 3 open to participants now, 3 under way, none of them phase 3. Atrial Fibrillation · Hospital Clinic of Barcelona.

Planned enrollment
6th of 11
104 · median 104
Started
2023
with 2 others
No phase
4 of 15
3 open now
Registered
14th of 15
by date

Among the 15 studies in Atrial Fibrillation by Hospital Clinic of Barcelona, this one is the 6th largest by planned enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2023, is one of 4 with no phase, and was the 14th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

3 of the 15 studies in Atrial Fibrillation by Hospital Clinic of Barcelona are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Atrial Fibrillation by Hospital Clinic of Barcelona, or all of them as a file.
02

Study summary

This randomised study will compare pulsed field ablation and cryoballoon ablation with respect to ablation lesion quality as assessed by late gadolinium enhancement (LGE) cardiac magnetic resonance (CMR) at 3 months post-ablation. Patients scheduled for first-time AF ablation will be randomised in a 2:1 fashion to receive PVI-only, either by pulsed field ablation (Farapulse Pulsed Field Ablation System, Boston Scientific) or cryoballoon ablation (Medtronic Cryoballoon Ablation System).

Read the detailed description

Pulmonary vein isolation (PVI) using catheter ablation has become a cornerstone in the treatment of AF and is considered the most effective therapy today. Catheter ablation has been mostly performed employing thermal energies, with radiofrequency and cryo-balloon ablation being the best validated most widely applied modalities. Despite substantial technological and procedural advances that have improved efficacy, efficiency and safety of AF ablation in recent years, long-term durability of ablation lesions is still not satisfactory, and rare but potentially life-threatening procedure-related complications like cardiac tamponade or atrio-esophageal fistula remain a concern. In addition, phrenic nerve palsy complicates a relevant proportion of procedures, particularly in cryo-ablation.

The novel non-thermal ablation method of pulsed field ablation holds great promise in that respect. Pulsed field ablation achieves permanent cell death through electroporation, which appears to provide a unique selectivity for cardiomyocytes and to spare surrounding tissues composed of other cell types, thus minimising the risk of collateral damage.This method has already been introduced into routine clinical practice and is established in many centers worldwide. A large number of studies have confirmed safety and efficacy of pulsed field ablation for pulmonary vein isolation in the context of AF and found significant reductions in ablation times. However, the putative benefits regarding efficacy, efficiency and safety remain to be proven in randomised controlled trials.

Against this background, the investigators aim to perform a randomised clinical trial comparing pulsed field ablation with thermal cryo-balloon ablation with respect to efficacy, effectiveness and safety. Patients scheduled for first-time AF ablation will be randomised in a 2:1 fashion to receive PVI-only, either by pulsed field ablation (Farapulse Pulsed Field Ablation System, Boston Scientific) or cryoballoon ablation (Medtronic Cryoballoon Ablation System). The primary outcome of this trial will be ablation lesion quality as assessed by late gadolinium enhancement (LGE) cardiac magnetic resonance (CMR) at 3 months post-ablation.

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

Keywords

  • Atrial fibrillation
  • Catheter ablation
  • Ablation lesion
  • Pulmonary vein isolation
  • Pulsed field ablation
  • Cryoballoon ablation
  • Cardiac magnetic resonance
  • Late gadolinium enhancement
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients scheduled for first-time atrial fibrillation catheter ablation

Exclusion criteria

Exclusion Criteria:

  • age \<18 years
  • long-standing persistent atrial fibrillation
  • prior left atrial ablation
  • pregnancy or lactation
  • reduced
  • \<30%
  • >35%
  • left atrial diameter >55 mm
  • cardiac implantable electronic device
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
104 participants (estimated)

Study arms

  • Experimental
    Pulsed Field Ablation

    Pulmonary vein isolation using the Farapulse Pulsed Field Ablation System (Boston Scientific)

    Procedure: Pulmonary vein isolation

  • Active comparator
    Cryoballoon Ablation

    Pulmonary vein isolation using the Medtronic Cryoballoon Ablation System

    Procedure: Pulmonary vein isolation

Interventions

  • ProcedurePulmonary vein isolation

    Catheter ablation

06

What researchers measure

Primary outcomes

  1. LGE-CMR-determined ablation lesion quality

    Complete late gadolinium enhancement encircling both pulmonarz vein pairs, with discontinuations adding up to less than 10% of the total length of the circumference

    Time frame: 3 months post-ablation

Secondary outcomes

  1. AF-free survival

    Time frame: 3, 6 and 12 months post-ablation

  2. Arrhythmia-free survival

    Freedom from atrial tachycardia, atrial flutter and AF

    Time frame: 3, 6 and 12 months post-ablation

  3. Time to first AF recurrence

    Time frame: 12, 24 and 36 months

  4. Progression from paroxysmal to persistent AF

    Time frame: 12, 24 and 36 months

  5. Time to first arrhythmia

    Time frame: 12, 24 and 36 months

  6. Spatial LGE distribution according to local wall thickness (as assessed by preablation CT)

    Time frame: 3 months post-ablation

  7. Complete pulmonary vein isolation confirmed by persistent entrance- and exit-block

    (per-pulmonary vein pair analysis and per-patient analysis

    Time frame: intra-procedural

  8. Safety events

    Vascular access complications, pericardial effusion / tamponade, phrenic nerve paly (temporal or permanent), atrio-esophageal fistula, esophageal ulcer, pulmonary vein stenosis, systemic embolism, stroke, TIA, death, cardiovascular death

    Time frame: periprocedural and 12 months

07

Study locations

1 of 1 sites recruiting
  • Hospital Clinic, University of Barcelona
    Barcelona, Catalonia 08036, Spain
    Recruiting
    • Ivo Roca-Luque, M.D. · Contactiroca@clinic.cat · +34932275551
    • Lluis Mont, M.D. · Sub investigator
    • Till F Althoff, M.D. · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Nov 2025, 24 months.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's 24 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2023
First posted
Jan 23, 2024
StartActual
Nov 1, 2023
Primary completionActual
Nov 1, 2025
CompletionEst.
Nov 1, 2026
Last update
Apr 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06220006
Responsible party
Ivo Roca (Head of Arrhythmia Section. Professor of Cardiology, Hospital Clinic of Barcelona) — Principal investigator
First posted
Jan 23, 2024
Start date
Nov 1, 2023
Primary completion
Nov 1, 2025
Completion
Nov 1, 2026 (estimated)
Last update
Apr 7, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion